NEO-LARYNGOBIS

Google image searchProduct monograph

Active ingredient

bismuth dipropylacetate, 135 MG

DIN: 00065927

Dosage form(s): SUPPOSITORY

Route(s) of administration: RECTAL

Schedule: OTC

Company: TEVA CANADA LIMITED

Date: 20-APR-2013

ATC:

• R02 — THROAT PREPARATIONS (ATC, ATC/DDD, )
• R02A — THROAT PREPARATIONS (ATC, ATC/DDD)
• R02AA — Antiseptics (ATC, ATC/DDD)
• R02AA20 — VARIOUS (ATC/DDD)

Pharmaceutical standard: MFR

External Links for Neo-Laryngobis

Search on Google

• Neo-Laryngobis side effects
• Neo-Laryngobis dosage
• bismuth dipropylacetate side effects
• bismuth dipropylacetate dosage

Teva Canada Limited

Go to Teva website to see drug product details. Sometimes you can find neo-laryngobis photos and/or monograph. If you are a healthcare professional, you may need to enter your license number.